Considerations for implementation of Alzheimer’s disease blood‐based biomarkers in clinical care based on recently updated NIA‐AA criteria
Michelle M Mielke · 2025
Read Considerations for implementation of Alzheimer’s disease blood‐based biomarkers in clinical care based on recently updated NIA‐AA criteria by Michelle M Mielke (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716091.txt.
Description
Michelle Mielke weighs what must be set ere blood marks for mind loss can run in day care, in a review from 2025. Fresh rules from two great bodies let blood marks sort the ill from kin ills. Marks span clump goods, nerve harm, swell, and a seed good, with blood vessel harm marks still to come.
Care tiers meet the marks with odd gains and blocks at each step. Open asks crowd: which mark, at what mark of ill, and how to stage the ill by blood in wards not labs. Drug fit calls also ride on the marks. Mass use waits on those calls, the review says.
Catalog record
| CREATOR | Michelle M Mielke |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |